The objectives of the Core are to enable large-scale production of helper-dependent adenoviral (HD-Ad) vectors for testing in small animals and nonhuman primates, and to provide expert technical support related to virus production. The Core will function as a shared resource among the projects of this program project, and is necessary due to the high cost of infrastructure, and to provide the expertise necessary to produce a large quantity of HD-Ad vectors. The physical characteristics of the facility will help assure the production of high quality vectors. These include the design of cell culture rooms, biosafety hoods, and physical separation of high titer virus from low titer virus during production phase. All equipment and supplies used at the facility will be approved for the production of biologicals used in pre-clinical studies. This includes certification by suppliers, quality assurance by the facility, and standard operating procedures (SOPs) for the receipt, inventory, expiration, and disposal of all material. All operations and procedures in the laboratory will be governed by SOPs. The Core will be responsible for the production of Master Cell Banks, Working Cell Banks, Master Helper-Virus Stocks, Working Helper-Virus Stocks, Master Vector Seeds, and Working Vector Seeds necessary for the production of the vectors under controlled conditions to allow for their use in laboratory animals and in pre-clinical studies. One of the major problems of HD-Ad vectors for clinical use is that of vector production capacity. The Core will be responsible to the development of methods for production of high quality HD-Ad vectors (<0.5% helper virus contamination) with high yield. The Core will exercise tight quality control to ensure the safety of end product materials, and to ensure the safety of the personnel involved in the production of the vectors. This will involve detailed record keeping, in-house quality assurance and the oversight of quality control tests. The operational director of the laboratory will be responsible for personnel training and compliance with all requirements for adenovirus production.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
2P01HL059314-06
Application #
6713768
Study Section
Project Start
2003-02-01
Project End
2007-12-31
Budget Start
2003-02-01
Budget End
2003-12-31
Support Year
6
Fiscal Year
2003
Total Cost
$182,135
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Wang, Leiming; Xu, Mafei; Qin, Jun et al. (2016) MPC1, a key gene in cancer metabolism, is regulated by COUPTFII in human prostate cancer. Oncotarget 7:14673-83
Oka, K; Mullins, C E; Kushwaha, R S et al. (2015) Gene therapy for rhesus monkeys heterozygous for LDL receptor deficiency by balloon catheter hepatic delivery of helper-dependent adenoviral vector. Gene Ther 22:87-95
Stephen, Sam Laurel; Montini, Eugenio; Sivanandam, Vijayshankar Ganesh et al. (2010) Chromosomal integration of adenoviral vector DNA in vivo. J Virol 84:9987-94
Li, Luoping; Xie, Xin; Qin, Jun et al. (2009) The nuclear orphan receptor COUP-TFII plays an essential role in adipogenesis, glucose homeostasis, and energy metabolism. Cell Metab 9:77-87
Brunetti-Pierri, Nicola; Stapleton, Gary E; Law, Mark et al. (2009) Efficient, long-term hepatic gene transfer using clinically relevant HDAd doses by balloon occlusion catheter delivery in nonhuman primates. Mol Ther 17:327-33
Koeberl, Dwight D; Sun, B; Bird, A et al. (2007) Efficacy of helper-dependent adenovirus vector-mediated gene therapy in murine glycogen storage disease type Ia. Mol Ther 15:1253-8
Koeberl, D D; Sun, B D; Damodaran, T V et al. (2006) Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia. Gene Ther 13:1281-9
Oka, Kazuhiro; Chan, Lawrence (2004) Liver-directed gene therapy for dyslipidemia and diabetes. Curr Atheroscler Rep 6:203-9
Zhao, B; Chua, S S; Burcin, M M et al. (2001) Phenotypic consequences of lung-specific inducible expression of FGF-3. Proc Natl Acad Sci U S A 98:5898-903